The Things Industries Celebrates 1.5 Million Connected Devices and Other Milestones During The Things Conference 2023
19.9.2023 17:00:00 EEST | Business Wire | Press release
The Things Industries, a global leader in LoRaWAN® Internet of Things (IoT) solutions, has announced 1.5 million devices connected to its robust network server infrastructure, The Things Stack, marking a new milestone in its journey towards operational excellence and product leadership in the LoRaWAN ecosystem. This and more announcements are being celebrated during the flagship event - The Things Conference, organized by The Things Industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230919065625/en/
The Things Industries has reached 1.5 million connected devices to its LoRaWAN Network Server (Graphic: Business Wire)
The company has emerged as a product leader and is widely respected for its operational excellence, uptime, and product completeness. Among its clients and partners are numerous Fortune 500 companies, utility companies, IoT product scale-ups, and a diverse range of system integrators.
This achievement underscores the company's commitment to product leadership and operational excellence in the market of LoRaWAN solution management software, and the ability to scale IoT projects for The Things Industries’ customers and partners. The Things Industries’ LoRaWAN platform is a global product that can be used in every industry vertical.
The recent report by Beecham Research validates the continued growth of LoRaWAN and the adoption across the world. As a global leader in the market of LoRaWAN network management software providers, The Things Industries validates these findings by seeing wide range adoption of the standard on its platform.
The Things Industries serve the market with its leading platform, The Things Stack Cloud, a managed LoRaWAN network server with advanced features and cloud capability that provides industry-leading uptimes with unlimited scalability. With the cloud capability, free and seamless upgrades come included.
The Things Conference, the company's flagship user event, will showcase the broad adoption and usage of the LoRaWAN standard and The Things Stack Cloud platform. The conference will feature over 100 device manufacturers, 110 speakers sharing their IoT experiences, and more than 60 concrete solutions with detailed business cases will be showcased. The Things Conference takes place on 21 and 22 September 2023 from 9 AM to 5 PM Central European Summer Time. The event will be streamed live worldwide.
Wienke Giezeman, CEO of The Things Industries, commented, "The Things Conference is a gathering where we celebrate hard-won successes in the LoRaWAN user space. IoT is a challenging field, and the level of innovation on display is growing every year. I anticipate engaging with the 1,000+ IoT innovators at our event."
About The Things Industries
Founded in 2015, The Things Industries is a leading provider of LoRaWAN IoT solutions, designed to offer secure and efficient connectivity. With a focus on driving efficiency and sustainability, the company estimates that its platform contributes to over $1 billion in efficiency gains for its customers.
For those interested in building IoT solutions based on LoRaWAN, The Things Industries offers a use case selector for product and service recommendations. To get started with the secure LoRaWAN Network Server, visit https://www.thethingsindustries.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919065625/en/
Contact information
Anastasia Grammatikopoulou, Marketing Manager, anastasia@thethingsindustries.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom